Results 111 to 120 of about 12,098 (189)

FISH molecular testing in cytological preparations from solid tumors [PDF]

, 2014
Many of the exciting new developments in solid tumor molecular cytogenetics impact classical and molecular pathology. Fluorescence in situ hybridization to identify specific DNA target sequences in nuclei of non-dividing cells in solid neoplasms has ...
CARIA, PAOLA, VANNI, ROBERTA
core   +1 more source

SEOM clinical guidelines for the treatment of non‑small cell lung cancer (2018) [PDF]

, 2018
Non-small cell lung cancer (NSCLC) accounts for up to 85% of all lung cancers. The last few years have seen the development of a new staging system, diagnostic procedures such as liquid biopsy, treatments like immunotherapy, as well as deeper molecular
Carcereny, Enric, García, Y., García-Campelo, Rosario, Guirado, M., Insa, A., Juan, O., Majem, Margarita, Provencio, M., Reguart, Noemi, Trigo, J. M., Universitat Autònoma de Barcelona   +10 more
core   +4 more sources

Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs [PDF]

, 2016
fusion between the EML4 (echinoderm microtubule-associated protein-like) and ALK (anaplastic lymphoma kinase) genes was identified in non-small cell lung cancer (NSCLC) in 2007 and there has been rapid progress in applying this knowledge to the benefit ...
Bayliss, R, Choi, J, Fennell, DA, Fry, AM, Richards, MW   +4 more
core   +2 more sources

Identification of FIG-ROS1 fusion in tumor ID 749 from Analysis of Receptor Tyrosine Kinase ROS1-Positive Tumors in Non–Small Cell Lung Cancer: Identification of a FIG-ROS1 Fusion

, 2023
<p>(A) Schematic representation of the genomic region containing fig and ros1. Probes set 1 derived from ros1 (orange) and the deleted region (green). Probe set 2 derived from ros1 (orange) and fig (green). (B,C) Yellow arrows point to split signals indicative of balanced translocation in the HCC78 cell line and white arrows point to intact ...
Herbert Haack, Xinmin Zhou, Matthew R. Silver, Jennifer S. Mack, Ting-Lei Gu, Meghan E. Kelly, Yerong Hu, Daiqiang Li, Katherine E. Crosby, Victoria M. Rimkunas   +9 more
openaire   +1 more source

A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer. [PDF]

, 2017
PurposeCabozantinib is a multi-kinase inhibitor that targets MET, AXL, and VEGFR2, and may synergize with EGFR inhibition in NSCLC. Cabozantinib was assessed alone or in combination with erlotinib in patients with progressive NSCLC and EGFR mutations who
Engelman, Jeffrey, Gettinger, Scott, Jänne, Pasi A, Lara, Primo N, Leach, Joseph, Miles, Dale R, Subramaniam, Deepa S, Wakelee, Heather A, Wax, Michael, West, Howard, Yaron, Yifah   +10 more
core   +2 more sources

CD74-ROS1 fusion transcripts in resected non-small cell lung carcinoma

Oncology Reports, 2013
The recent discovery of fusion oncokinases in a subset of non-small cell lung carcinomas (NSCLCs) is of considerable clinical interest, since NSCLCs that express such fusion oncokinases are reportedly sensitive to kinase inhibitors. To better understand the role of recently identified ROS1 and RET fusion oncokinases in pulmonary carcinogenesis, we ...
Shun, Matsuura, Kazuya, Shinmura, Takaharu, Kamo, Hisaki, Igarashi, Kyoko, Maruyama, Mari, Tajima, Hiroshi, Ogawa, Masayuki, Tanahashi, Hiroshi, Niwa, Kazuhito, Funai, Takashi, Kohno, Takafumi, Suda, Haruhiko, Sugimura   +12 more
openaire   +3 more sources

TKI-addicted ROS1-rearranged cells are destined to survival or death by the intensity of ROS1 kinase activity

Scientific Reports, 2017
ROS1 rearrangement is observed in 1–2% of non-small cell lung cancers (NSCLC). The ROS1 tyrosine kinase inhibitor (TKI) crizotinib has induced marked tumour shrinkage in ROS1-rearranged cancers.
Hayato Ogura, Yuka Nagatake-Kobayashi, Jun Adachi, Takeshi Tomonaga, Naoya Fujita, Ryohei Katayama   +5 more
doaj   +1 more source

Investigating the benefits of molecular profiling of advanced non-small cell lung cancer tumors to guide treatments. [PDF]

, 2018
In this study we utilized data on patient responses to guided treatments, and we evaluated their benefit for a non-small cell lung cancer cohort. The recommended therapies used were predicted using tumor molecular profiles that involved a range of ...
Alifrangis, C, Belluz, LDB, Carter, P, Cereser, B, Chandrasinghe, P, Krell, J, Lim, E, Moderau, N, Poyia, F, Stebbing, J, Tabassum, N, Zhang, H   +11 more
core   +2 more sources

Detection of ALK fusion transcripts in FFPE lung cancer samples by NanoString technology [PDF]

, 2017
Background: ALK-rearranged lung cancers exhibit specific pathologic and clinical features and are responsive to anti-ALK therapies. Therefore, the detection of ALK-rearrangement is fundamental for personalized lung cancer therapy. Recently, new molecular
A Cesano, Adriana Cruvinel Carloni, Adriane F. Evangelista, AP Becker, AS Crystal, AT Shaw, Cristovam Scapulatempo-Neto, DR Camidge, DW-S Wong, EL Kwak, EM Gaughan, FH Wilson, Flávia E. de Paula, I Dagogo-Jack, Iberê Cauduro Soares, J Wu, JM Heuckmann, Jose Elias Miziara, JS Reis-Filho, K McKeage, K Rikova, K Takeuchi, LS Yamane, M Soda, Maicon F. Zanon, Maressa Ferreira-Neto, Mariana Andozia Morini, ME Lira, MM Kulkarni, MW Wynes, Pedro de Marchi, R Roskoski, Rui M. Reis, S-H Jung, SM Ali, SW Morris, T-M Rogers, YP Mossé   +37 more
core   +2 more sources

ROS1 fusions in Chinese patients with non-small-cell lung cancer

Annals of Oncology, 2013
To determine the prevalence and clinicopathological features of ROS1 fusions in Chinese patients with non-small-cell lung cancer (NSCLC).Formalin-fixed and paraffin-embedded (FFPE) tissue sections from 392 patients with NSCLC were screened for ROS1 fusions by multiplex RT-PCR and all ROS1 fusions were validated by direct sequencing.
Cai, W., Li, X., Su, C., Fan, L., Zheng, L., Fei, K., Zhou, C., Manegold, C., Schmid-Bindert, G.   +8 more
openaire   +3 more sources